drug · antibody
patient view →satralizumab
Phase 3updated 2mo agoby F. Hoffmann-La Roche Ltd🔗 ChEMBL
Phase 3community read0 votes
Antibody drug with a maximum clinical stage of Approval (across all indications), with an approval for neuromyelitis optica and immune system disease and 7 investigational indications.
indications
indications
Duchenne Muscular Dystrophy
targets
IL6Ralpha/GP130
all catalysts(0)
nothing on the calendar yet
News(0)
no news has mentioned this drug yet
comments(0)
5-min edit window · permanent after that